Research programme: protein vaccines - ApoVax
Alternative Names: ApoFasL; ApoVax104; ApoVax104-HPVLatest Information Update: 04 Nov 2017
At a glance
- Originator ApoVax
- Class Protein vaccines
- Mechanism of Action CD95 antigen inhibitors; Human papillomavirus E7 protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Cervical cancer; Human papillomavirus infections; Tuberculosis; Type 1 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cervical-cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Human-papillomavirus-infections in USA (Parenteral)